Simba Gill, Evelo Biosciences CEO

Sim­ba Gill stay­ing on at Evelo to weath­er lay­offs and a PhII fail

Sim­ba Gill will be stay­ing put as CEO of Evelo Bio­sciences for now.

Gill an­nounced last year that he would be leav­ing the head po­si­tion at Evelo to take on the role of ex­ec­u­tive part­ner at Flag­ship Pi­o­neer­ing. He was aim­ing to stay on un­til a suc­ces­sor was se­lect­ed, but there’s a new course of ac­tion in the wake of a Phase II miss and a re­duced head­count.

“I want to em­pha­size that I re­main per­son­al­ly com­mit­ted to Evelo and stay­ing on to lead the or­ga­ni­za­tion. I con­tin­ue to be­lieve that Evelo is a re­mark­able op­por­tu­ni­ty in terms of the sci­ence, the plat­form, the type of prod­ucts that we’re able to pro­duce, and most im­por­tant­ly, the po­ten­tial of mil­lions of pa­tients suf­fer­ing from all stages of in­flam­ma­to­ry dis­ease,” Gill said on a con­fer­ence call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.